Filtered By:
Vaccination: Influenza Vaccine

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 6653 results found since Jan 2013.

Validation of Multi-epitope Peptides Encapsulated in PLGA Nanoparticles Against Influenza A Virus
CONCLUSION: The study demonstrated the self-adjuvanting properties of the PLGA nanoparticles as a delivery system without the need for incorporation of toxic and costly conventional adjuvants in multi-epitope peptide-based vaccines.PMID:37344603 | DOI:10.1007/s11095-023-03540-x
Source: Cell Research - June 21, 2023 Category: Cytology Authors: Wen Tzuen Heng Hui Xuan Lim Kuan Onn Tan Chit Laa Poh Source Type: research

Layered protein nanoparticles containing influenza B HA stalk induced sustained cross-protection against viruses spanning both viral lineages
In this study, we generated structure-stabilized HA stalk antigens from influenza B and fabricated double-layered protein nanoparticles as universal influenza B vaccine candidates. In vitro studies found that the resulting protein nanoparticles were effectively taken up to activate dendritic cells. Nanoparticle immunization induced broadly reactive immune responses conferring robust and sustained cross-immune protection against influenza B virus strains of both lineages. The results reveal the potential of layered protein nanoparticles incorporated with structure-stabilized constant antigens as a universal influenza vaccin...
Source: Biomaterials - July 10, 2022 Category: Materials Science Authors: Yufeng Song Wandi Zhu Ye Wang Lei Deng Yao Ma Chunhong Dong Gilbert X Gonzalez Joo Kim Lai Wei Sang-Moo Kang Bao-Zhong Wang Source Type: research

T4 bacteriophage nanoparticles engineered through CRISPR provide a versatile platform for rapid development of flu mucosal vaccines
Antiviral Res. 2023 Jul 27:105688. doi: 10.1016/j.antiviral.2023.105688. Online ahead of print.ABSTRACTVaccines that trigger mucosal immune responses at the entry portals of pathogens are highly desired. Here, we showed that antigen-decorated nanoparticle generated through CRISPR engineering of T4 bacteriophage can serve as a universal platform for the rapid development of mucosal vaccines. Insertion of Flu viral M2e into phage T4 genome through fusion to Soc (Small Outer Capsid protein) generated a recombinant phage, and the Soc-M2e proteins self-assembled onto phage capsids to form 3M2e-T4 nanoparticles during propagatio...
Source: Antiviral Research - July 29, 2023 Category: Virology Authors: Mengling Li Cen Chen Xialin Wang Pengju Guo Helong Feng Xueqi Zhang Wanpo Zhang Changqin Gu Jingen Zhu Guoyuan Wen Yaoyu Feng Lihua Xiao Guiqing Peng Venigalla B Rao Pan Tao Source Type: research

Preparation and immunological evaluation of inactivated avian influenza virus vaccine encapsulated in chitosan nanoparticles
Publication date: Available online 8 November 2017 Source:Biologicals Author(s): Samah H. Mohamed, Abdel Satar Arafa, Wesam H. Mady, Hanan A. Fahmy, Lamiaa M. Omer, Rania E. Morsi Efficacy maximization of inactivated avian influenza vaccine using safe adjuvants was investigated. Chitosan nanoparticles were prepared by ionic gelation method with average size of 150 nm and their Zeta potential was 11.5 mV. After encapsulation of avian influenza vaccine, the average size was 397 nm and Zeta potential was 4.29 mV. The highest HI antibody titer results were shown in chicken group vaccinated with inactivated avian influenza...
Source: Biologicals - November 8, 2017 Category: Biology Source Type: research

Preparation and immunological evaluation of inactivated avian influenza virus vaccine encapsulated in chitosan nanoparticles.
Abstract Efficacy maximization of inactivated avian influenza vaccine using safe adjuvants was investigated. Chitosan nanoparticles were prepared by ionic gelation method with average size of 150 nm and their Zeta potential was 11.5 mV. After encapsulation of avian influenza vaccine, the average size was 397 nm and Zeta potential was 4.29 mV. The highest HI antibody titer results were shown in chicken group vaccinated with inactivated avian influenza virus AIV-chitosan followed by the group vaccinated with inactivated AIV-chitosan nanoparticles then the group vaccinated with oil inactivated AIV vaccine, on usi...
Source: Biologicals : Journal of the International Association of Biological Standardization - November 8, 2017 Category: Biotechnology Authors: Mohamed SH, Arafa AS, Mady WH, Fahmy HA, Omer LM, Morsi RE Tags: Biologicals Source Type: research

Engineering of papaya mosaic virus (PapMV) nanoparticles with a CTL epitope derived from influenza NP
Conclusion: The point of fusion on the PapMV vaccine platform is critical to triggering an efficient CTL response. Efficacy is linked to nanoparticle stability; nanoparticles must be stable at 37°C but remain susceptible to cellular proteases to ensure efficient processing of the CTL epitope by cells of the immune system. The results of this study improve our understanding of the PapMV vaccine platform, which will facilitate the design of efficient vaccines to various infectious threats.
Source: Journal of Nanobiotechnology - April 4, 2013 Category: Nanotechnology Authors: Cindy BabinNathalie MajeauDenis Leclerc Source Type: research

Structural and antigenic stability of H5N1 hemagglutinin trimer upon release from polyanhydride nanoparticles.
Abstract While H5N1 avian influenza has not yet acquired the capacity to readily infect humans, should it do so, this viral pathogen would present an increasing threat to the immunologically naïve human population. Subunit vaccines based on the viral glycoprotein hemagglutinin (HA) can provide protective immunity against influenza. Polyanhydride nanoparticles have been shown to enhance efficacy of subunit vaccines, providing the dual advantages of adjuvanticity and sustained delivery resulting in enhanced protein stability and immunogenicity. In this work, a recombinant trimer of H5 (H53 ) was encapsulated and re...
Source: Biomed Res - January 17, 2014 Category: Research Authors: Ross KA, Loyd H, Wu W, Huntimer L, Wannemuehler MJ, Carpenter S, Narasimhan B Tags: J Biomed Mater Res A Source Type: research

Self-Assembled Ferritin Nanoparticles Expressing Hemagglutinin as an Influenza Vaccine
NIH inventors at the Vaccine Research Center have developed a novel influenza virus hemagglutinin (HA)-ferritin nanoparticle influenza vaccine that is easily manufactured, potent, and elicits broadly neutralizing influenza antibodies against multiple strains of influenza. This novel influenza nanoparticle vaccine elicited two types of broadly neutralizing, cross-protective antibodies, one directed to the highly conserved HA stem and a second proximal to the conserved receptor binding site (RBS) of the viral HA, providing a new platform for universal and seasonal influenza. In addition, HA-ferritin nanoparticles can be easi...
Source: NIH OTT Licensing Opportunities - July 20, 2012 Category: Research Authors: admin Source Type: research

ISCOMs/MPLA ‐Adjuvanted SDAD Protein Nanoparticles Induce Improved Mucosal Immune Responses and Cross‐Protection in Mice
In this study, novel protein nanoparticles are generated by conjugating the influenza M2e-NA fusion protein onto influenza nucleoprotein nanoparticle cores using a hetero-bifunctional crosslinker SDAD (NHS-SS-Diazirine).   The resulting protein nanoparticles, when formulated with ISCOMs/monophosphoryl lipid A adjuvants, exhibit significantly improved immune responses in both systemic and local mucosal compartments. These outcomes position this formulation as a promising mucosal vaccine candidate. AbstractThe epidemics caused by the influenza virus are a serious threat to public health and the economy. Adding appropriate a...
Source: Small - May 10, 2023 Category: Nanotechnology Authors: Wandi Zhu, Jaeyoung Park, Thomas Pho, Lai Wei, Chunhong Dong, Joo Kim, Yao Ma, Julie A. Champion, Bao ‐Zhong Wang Tags: Research Article Source Type: research

Validation of Multi-epitope Peptides Encapsulated in PLGA Nanoparticles Against Influenza A Virus
ConclusionThe study demonstrated the self-adjuvanting properties of the PLGA nanoparticles as a delivery system without the need for incorporation of toxic and costly conventional adjuvants in multi-epitope peptide-based vaccines.
Source: Pharmaceutical Research - June 21, 2023 Category: Drugs & Pharmacology Source Type: research

PapMV nanoparticles improve mucosal immune responses to the trivalent inactivated flu vaccine
Conclusions: We demonstrate for the first time that PapMV nanoparticles are an effective and potent mucosal adjuvant for vaccination.
Source: Journal of Nanobiotechnology - May 3, 2014 Category: Nanotechnology Authors: Gervais RiouxClaudia MathieuAlexis RussellMarilène BolducMarie-Eve Laliberté-GagnéPierre SavardDenis Leclerc Source Type: research

Conjugating influenza a (H1N1) antigen to n‐trimethylaminoethylmethacrylate chitosan nanoparticles improves the immunogenicity of the antigen after nasal administration
This article is protected by copyright. All rights reserved
Source: Journal of Medical Virology - May 8, 2015 Category: Virology Authors: Qingfeng Liu, Xiaoyao Zheng, Chi Zhang, Xiayan Shao, Xi Zhang, Qizhi Zhang, Xinguo Jiang Tags: Research Article Source Type: research